Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Sanford-Burnham to Partner with Pfizer

Published: Tuesday, August 20, 2013
Last Updated: Tuesday, August 20, 2013
Bookmark and Share
The collaboration will see the organisations identify new therapeutic targets for preventing and treating complications of obesity and diabetes.

The team will utilize novel screening tools including systems-biology approaches and technologies developed at the Institute with the aim of discovering new therapeutic strategies for reducing insulin resistance in obesity and diabetes. 

Under the three-year agreement, multi-disciplinary teams from Sanford-Burnham and Pfizer will collaborate to identify and validate new targets for drug discovery. The collaboration combines our expertise in fundamental disease biology and muscle metabolism with Pfizer’s expertise in drug discovery. Investigators will utilize the Conrad Prebys Center for Chemical Genomics to screen for new relevant targets using investigational compounds from Pfizer as well as evaluate compounds previously identified from the NIH chemical library. Once the screening identifies compounds of interest, Sanford-Burnham and Pfizer scientists will collaborate to characterize and further study the “hit” compounds to understand their mechanism of action. These compounds will then be used as “probes” to identify novel therapeutic targets for the treatment of diabetes. 

Finding new medicines for diabetes 
“Diabetes presents an enormous public health burden. There is an acute need to translate innovative science into potential new medicines for people living with this debilitating disease,” said Tim Rolph, Vice President and Head of Cardiovascular and Metabolic Diseases Research Unit at Pfizer. “Pfizer’s collaboration with Sanford-Burnham to use their cutting-edge screen designs is an example of our strategy to work with academic innovators to discover novel therapeutics for prevention and treatment of diabetes.” Pfizer will have access to Sanford-Burnham’s team of world-class scientists and translational infrastructure dedicated to finding new approaches to targeting disease. Collaborating with researchers at a major pharmaceutical company will help us achieve our mission of translating high-impact science into new therapies. “This important collaboration focuses our tremendous scientific and translational firepower on a major medical problem – complications of obesity-related diabetes. Working with Pfizer, we can more quickly bridge the gap between basic and translational research,” said Stephen Gardell, Ph.D., senior director of scientific resources in our Diabetes and Obesity Research Center. 

Advancing drug discovery in the Prebys Center
The Prebys Center houses Sanford-Burnham’s state-of-the-art screening facility established to accelerate the rate of commercialization of basic research in an independent medical research setting. Our discovery capabilities include: ultra-high throughput screening, high-content screening, phenotypic screening, and target-deconvolution technologies. The Prebys Center is led and staffed by industry-trained professionals who work closely with Sanford-Burnham investigators and industry collaborators to translate scientific findings into actionable drug discovery projects.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

A Cautionary Tale on Genome-Sequencing Diagnostics for Rare Diseases
Studies in several children have raising new questions about inheritance, genomic sequencing, and diagnostic.
Tuesday, May 14, 2013
“Junk DNA” Drives Embryonic Development
An embryo is an amazing thing. From just one initial cell, an entire living, breathing body emerges, full of working cells and organs.
Thursday, December 06, 2012
Scientific News
Lung Repair and Regeneration Gene Discovered
New role for hedgehog gene offers better understanding of lung disease.
How Cell Growth Triggers Cell Division
Researchers in Jan Skotheim's lab have discovered a previously unknown mechanism that controls how large cells grow, an insight that could one day provide insight into attacking diseases such as cancer.
Microbe Sleuth
Tanja Bosak examines how life and the Earth evolved in tandem during their early history together.
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Restoring Vision with Stem Cells
Age-related macular degeneration (AMRD) could be treated by transplanting photoreceptors produced by the directed differentiation of stem cells, thanks to findings published today by Professor Gilbert Bernier of the University of Montreal and its affiliated Maisonneuve-Rosemont Hospital.
The Age of Humans Controlling Microbes
Engineered bacteria could soon be used to detect environmental toxins, treat diseases, and sustainably produce chemicals and fuels.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
Metabolomic Platform Reveals Fundamental Flaw in Common Lab Technology
A new study led by scientists at The Scripps Research Institute (TSRI) shows that a technology used in thousands of laboratories, called gas chromatography mass spectrometry (GC-MS), fundamentally alters the samples it analyzes.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos